Infiltration of Lynch colorectal cancers by activated immune cells associates with early staging of the primary tumor and absence of lymph node metastases - PubMed (original) (raw)

Infiltration of Lynch colorectal cancers by activated immune cells associates with early staging of the primary tumor and absence of lymph node metastases

Noel F C C de Miranda et al. Clin Cancer Res. 2012.

Abstract

Purpose: Lynch syndrome colorectal cancers often lose human leukocyte antigen (HLA) class I expression. The outgrowth of clones with immune evasive phenotypes is thought to be positively selected by the action of cytotoxic T cells that target HLA class I-positive cancer cells. To investigate this hypothesis, we related the type and density of tumor lymphocytic infiltrate in Lynch colorectal cancers with their HLA class I phenotype and clinicopathologic stage.

Experimental design: HLA class I expression was assessed by means of immunohistochemistry. Characterization of tumor-infiltrating lymphocytes was carried out by using a triple immunofluorescence procedure that allowed the simultaneous detection of CD3-, CD8-, and granzyme B (GZMB)-positive cells. Additional markers were also used for further characterization of an elusive CD3(-)/CD8(-)/GZMB(+) cell population.

Results: We discovered that high tumor infiltration by activated CD8(+) T cells correlated with aberrant HLA class I expression and associated with early tumor stages (P < 0.05). CD8(+) T cells were most abundant in HLA class I heterogeneous tumors (P = 0.02) and frequent in HLA class I-negative cases (P = 0.04) when compared with HLA class I-positive carcinomas. An elusive immune cell population (CD45(+)/CD8(-)/CD56(-)/GZMB(+)) was characteristic for HLA class I-negative tumors lacking lymph node metastases (P < 0.01).

Conclusions: The immune system assumes an important role in counteracting the progression of Lynch colorectal cancers and in selecting abnormal HLA class I phenotypes. Our findings support the development of clinical strategies that explore the natural antitumor immune responses occurring in Lynch syndrome carriers.

PubMed Disclaimer

Cited by

Immunoprofiles of colorectal cancer from Lynch syndrome.
Walkowska J, Kallemose T, Jönsson G, Jönsson M, Andersen O, Andersen MH, Svane IM, Langkilde A, Nilbert M, Therkildsen C. Walkowska J, et al. Oncoimmunology. 2018 Sep 26;8(1):e1515612. doi: 10.1080/2162402X.2018.1515612. eCollection 2019. Oncoimmunology. 2018. PMID: 30546958 Free PMC article.
HLA class I loss in colorectal cancer: implications for immune escape and immunotherapy.
Anderson P, Aptsiauri N, Ruiz-Cabello F, Garrido F. Anderson P, et al. Cell Mol Immunol. 2021 Mar;18(3):556-565. doi: 10.1038/s41423-021-00634-7. Epub 2021 Jan 20. Cell Mol Immunol. 2021. PMID: 33473191 Free PMC article. Review.
Immunogenomic Biomarkers and Validation in Lynch Syndrome.
Chambuso R, Mthembu M, Kaambo E, Robertson B, Ramesar R. Chambuso R, et al. Cells. 2023 Feb 2;12(3):491. doi: 10.3390/cells12030491. Cells. 2023. PMID: 36766832 Free PMC article.
CXCR6+ Tumor-Associated Macrophages Identify Immunosuppressive Colon Cancer Patients with Poor Prognosis but Favorable Response to Adjuvant Chemotherapy.
Chang J, Lin S, Mao Y, Xu Y, Zhang Z, Wu Q, Chen Y, Wei Y, Feng Q, Xu J. Chang J, et al. Cancers (Basel). 2022 Sep 24;14(19):4646. doi: 10.3390/cancers14194646. Cancers (Basel). 2022. PMID: 36230570 Free PMC article.
Lymph Node Ratio as a Risk Factor for Recurrence After Adjuvant Chemotherapy in Stage III Colorectal Cancer.
Ooki A, Akagi K, Yatsuoka T, Asayama M, Hara H, Nishimura Y, Katoh H, Yamashita K, Watanabe M, Yamaguchi K. Ooki A, et al. J Gastrointest Surg. 2017 May;21(5):867-878. doi: 10.1007/s11605-017-3382-5. Epub 2017 Mar 1. J Gastrointest Surg. 2017. PMID: 28251467

Infiltration of Lynch colorectal cancers by activated immune cells associates with early staging of the primary tumor and absence of lymph node metastases - PubMed (original) (raw)